Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Truist Securities Downgrades Maxar Technologies to Hold, Announces $53 Price Target

Truist Securities analyst Michael Ciarmoli downgrades Maxar Technologies (NYSE:MAXR) from Buy to Hold and announces $53 price target.
byBenzinga Newsdesk
December 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Truist Securities analyst Michael Ciarmoli downgrades Maxar Technologies (NYSE:MAXR) from Buy to Hold and announces $53 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Cantex Pharmaceuticals Obtains Exclusive Worldwide Rights To Intellectual Property From Georgetown University For Azeliragon As A Potential Treatment Of Cancer-related Cognitive Decline; NOTE: Azeliragon Was Discovered By vTv And Licensed To Cantex Pha…

By Happy Mohamed
June 1, 10:49 AM
Cantex to Expand Collaboration with Georgetown's Lombardi Comprehensive Cancer Center WESTON, Fla., June 1, 2023 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical

VTVT